AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's Disease. Click to read why ACIU is a Buy.

Recent strategic collaborations are strengthening ACI Worldwide's foothold in the expanding digital payments infrastructure sector. The company's latest part ...

MIAMI--(BUSINESS WIRE)--ACI Worldwide (NASDAQ: ACIW), a global leader in mission-critical, real-time payment solutions, today announced that its award-winning fraud protection services are now ...

These changes translate into lower transaction costs, greater predictability, and stronger confidence among global supply chain partners ...